Press & News

ViewReleaseInStandardHtml

Boule Diagnostics – Changes to nominations committee ahead of the 2017 AGM

Following publication of the Boule nomination committee ahead of the 2017 Annual General Meeting, a change to its composition of members has been made due to the change in ownership at Boule. Staffan Persson who represented Zimbrine Holding B.V. has left the nomination committee. His replacement is Thomas Eklund, who represents himself.

The nomination committee accordingly now comprises the following members:

-       Ulf Hedlundh, Svolder AB (chair)

-       Emil Hjalmarsson, AB Grenspecialisten

-       Thomas Eklund

Shareholders who wish to contact the nomination committee are invited to contact the chair of the committee, Ulf Hedlundh, by phone to +46 8 440 37 73 or by email ulf.hedlundh@svolder.se
 

About Boule Diagnostics AB

Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary hematology. The group is comprised of operating subsidiaries in Sweden, the US and China. The Boule Diagnostics share is traded on NASDAQ Nordic since 2011. www.boule.se 

This information is information that Boule Diagnostics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:00 CET January 17, 2016.